Fortunately, numerous targeted agents for advanced GC are under extensive investigation, primarily targeting human epidermal growth factor receptor 2 (HER2), microsatellite instability-high/deficient mismatch repair, claudin 18.2 (CLDN18.2), vascular endothelial growth factor/vascular endothelial growth factor receptor, and fibroblast growth factor receptor (FGFR2), among others [3]. This evidence concerns the gene ERBB2 and gastric cancer.